Nabla Bio has entered a new multi-year research collaboration with Takeda to advance the AI-driven design of protein therapeutics.
Nabla Bio will receive an upfront payment along with research funding, and is eligible for success-based payments exceeding $1bn in total.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This agreement marks the second collaboration between the two companies.
The partnership will implement Nabla Bio’s biomolecular design platform, known as the Joint Atomic Model (JAM), within Takeda’s development programmes that are in early stages.
It will involve the de novo design of antibodies in parallel for challenging targets, multispecifics and other custom therapeutics.
Nabla Bio co-founder and CEO Surge Biswas stated: “Since 2022, we’ve collaborated with Takeda to push the boundaries of next-generation biologics discovery.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This second collaboration builds on the success of our first programme and reflects our shared conviction that de novo design and AI-driven optimisation, powered by foundation models like JAM, can unlock entirely new therapeutic spaces and accelerate the development of new medicines at a scale and speed not seen before.”
JAM has exhibited success rates in de novo design across a range of targets, including the creation of picomolar binders to G protein-coupled receptors in zero-shot scenarios.
Nabla’s AI-designed therapeutics exhibit preclinical properties such as minimal immunogenicity, pharmacodynamics, pharmacokinetics and functionality in non-human primates.
Takeda chief scientific officer and head of research Chris Arendt stated: “At Takeda, we are accelerating drug development by leveraging the latest advances in AI.
“Building upon the success of our first engagement with Nabla Bio, this collaboration applies their cutting-edge AI and wet lab to help us design and optimise protein therapeutics for applications across our therapeutic areas.”
